- News Home
12 December 2013 1:00 pm ,
Vol. 342 ,
The iconic 125-year-old Lick Observatory on Mount Hamilton near San Jose, California, is facing the threat of closure...
Recent results from the Curiosity Mars rover have helped scientists formulate a plan for the next phase of its mission...
A new, remarkably powerful drug that cripples the hepatitis C virus (HCV) came to market last week, but it sells for $...
In pretoothbrush populations, gumlines would often be marred by a thick, visible crust of calcium phosphate, food...
Evolutionary biologists have long studied how the Mexican tetra, a drab fish that lives in rivers and creeks but has...
Victorian astronomers spent countless hours laboriously charting the positions of stars in the sky. Such sky mapping,...
In an ambitious project to study 1000 years of sickness and health, researchers are excavating the graveyard of the now...
Stefan Behnisch has won awards for designing science labs and other buildings that are smart, sustainable, and...
- 12 December 2013 1:00 pm , Vol. 342 , #6164
- About Us
New Pharmaceutical Firm With Hefty R&D
2 June 1998 7:30 pm
Overnight, a pharmaceutical giant has been born, as two U.S. companies--Monsanto of St. Louis and American Home Products Inc. (AHP), of Madison, New Jersey--announced Monday that they will merge. The new corporation, which still has no name, will devote $2 billion of its consolidated annual research budget to pharmaceuticals and the remaining $1 billion to agricultural projects. This puts it on par with other big R&D spenders such as Merck & Co. of Whitehouse Station, New Jersey, and Pfizer Inc. of New York City.
The new corporation will operate under an unusual dual governance: Both Monsanto's chief Robert Shapiro and AHP's chief John Stafford will serve as its CEOs. Together, the co-CEOs will administer a $35 billion manufacturing empire that markets all manner of products--from Monsanto's weed killer Roundup, to over-the-counter drugs like AHP's Advil, to new gene-based medicines. Among the pharmaceutical subsidiaries that will come under their umbrella are such firms as the Genetics Institute of Cambridge, Massachusetts, G. D. Searle of Skokie, Illinois, Immunex Corp. of Seattle, and Wyeth-Ayerst of Philadelphia.
This merger "reflects the fact that the cost of developing [new] pharmaceuticals is so high," says Jeff Trewhitt, spokesperson for the Pharmaceutical Research and Manufacturing Association in Washington, D.C. He estimates that it now costs between $300 million and $600 million to research and develop a new biomedical product, way up from the 1976 average cost of around $125 million per product.
Companies require "massive" research budgets, Trewhitt says, to remain competitive in the drug industry. One way to achieve that mass is to consolidate. Bill Gans, CEO of the biotech firm Pathogenesis of Seattle, agrees: Even big pharmaceutical companies are searching for ways to assemble funds to support more research, he says, because it "requires enormous investments to stay in the areas where new technologies are being developed."